Search Results for: formulation development amorphous dispersion formu
Articles
SPECIAL FEATURE - Improving Bioavailability & Solubility: Understand Your Molecule March 3, 2020
Contributor Cindy H. Dubin asked several leading companies about how they are currently overcoming today’s most pressing bioavailability and solubility challenges for their pharma clients.
Catalent Invests $40 Million to Increase Patient-Centric Dose Form Manufacturing Capabilities May 2, 2019
Catalent recently announced it is investing up to $40 million at its manufacturing facility in Winchester, KY. The investment will...SPECIAL FEATURE - Challenging Molecules Drive Developers to Get More Creative With Excipients April 2, 2018
Contributor Cindy H. Dubin highlights the techniques various excipient manufacturers are using to develop more innovative and effective ingredients to improve the performance of drug molecules.
SPECIAL FEATURE - Improving Bioavailability & Solubility: A Top-Down Versus Bottom-Up Approach March 15, 2018
Contributor Cindy H. Dubin speaks with several innovative companies on their science, techniques, and technologies aimed at improving bioavailability and solubility.
Advances in Continuous Manufacturing of Drug Product, Commercial Spray Drying & HPAPIs/SDD at Hovione May 15, 2017
Applying extensive knowledge, data, and a Development by Design (DbD) approach has enabled Hovione to accelerate spray drying development; reducing...CONTROLLED RELEASE - Leveraging Precision Particle Fabrication® Technology to Create Patient-Friendly Dosage Forms May 2, 2017
Cory Berkland, PhD, and Nathan Dormer, PhD, review how controlled-release powders offer a flexible and efficient approach to addressing a multitude of patient populations, while also improving compliance.
SPECIAL FEATURE - Bioavailability & Solubility: New Approaches to Enhance Drug Performance February 27, 2017
Contributor Cindy H. Dubin highlights many of the latest techniques to enhance bioavailability and solubility, how to determine the right technique for your compound, and how some companies are realizing faster time to market as a result.
Ascendia Pharmaceuticals Announces Issuance of New Patent for Acute Coronary Syndrome Program February 17, 2017
Ascendia Pharmaceuticals, a specialty pharmaceutical company engaged in nano-formulation design, development, and manufacture for poorly soluble molecules, recently announced it...Ascendia Pharmaceuticals Announces Issuance of New Patent for Acute Coronary Syndrome Program February 17, 2017
Ascendia Pharmaceuticals, a specialty pharmaceutical company engaged in nano-formulation design, development, and manufacture for poorly soluble molecules, recently announced it...SPECIAL FEATURE - Analytical Testing: Market Drivers, Growing Demand & Client Needs January 17, 2017
Contributor Cindy H. Dubin spoke with several testing providers to find out what services they offer, trends they identify, and how they have specifically addressed clients’ needs throughout the past year.
Q&A: Scientific Advances Address Challenges Posed by Poor Solubility of Drug Candidates June 14, 2016
At Metrics Contract Services, Dr. Michael DeHart manages all aspects of personnel and operations relating to formulating and manufacturing...Q&A: Scientific Advances Address Challenges Posed by Poor Solubility of Drug Candidates June 14, 2016
At Metrics Contract Services, Dr. Michael DeHart manages all aspects of personnel and operations relating to formulating and manufacturing...SPECIAL FEATURE - Excipients: Manufacturers Look to Co-Processing as a Way of Improving Functionality June 2, 2016
Contributor Cindy H. Dubin reports how leading excipient manufacturers are overcoming their own R&D challenges to deliver innovative excipients that address problems associated with both large and small molecules.
LIPOPHILIC SALTS - Opportunities & Applications in Oral Drug Delivery June 1, 2016
Hywel Williams, PhD, Annabel Igonin, PhD, David Vodak, PhD, and Hassan Benameur, PhD, believe lipophilic salts are being explored in a number of different areas and one interesting application is their potential to boost API loading in lipid formulations.
Ascendia Pharma Announces New Contract Manufacturing Capability to Deliver cGMP Phase I Clinical Trial Materials March 18, 2016
Ascendia now offers cGMP manufacturing capabilities for both oral and parenteral dosage forms to support your Phase I clinical trials. We...SPECIAL FEATURE - Advancements in Drug Delivery Technologies Tackle Solubility & Bioavailability Challenges February 29, 2016
Contributor Cindy H. Dubin speaks with several innovator companies to learn more about the latest advances in drug delivery to address the challenging issues of solubility and bioavailability today
SPECIAL FEATURE - Analytical Testing: Using More Sophisticated Tools to Support Small & Large Molecule Projects January 8, 2016
Contributor Cindy H. Dubin recently spoke with leading analytical testing providers to find out what services they offer and what equipment they use to handle both small and large molecules for their pharma clients.
SOLUBILIZATION TECHNOLOGY - How to Choose the Right Solubilization Technology for Your API October 5, 2015
Matt Wessel, PhD, Tom Reynolds, PhD, Sanjay Konagurthu, PhD, and Marshall Crew, PhD, present a brief overview of the various solubilization technologies, and a high-level strategy to aid in the selection of an appropriate formulation technology.
HOT MELT EXTRUSION - OptiMelt™ Hot Melt Extrusion Technology to Improve Bioavailability of Poorly Soluble Drugs August 31, 2015
Sampada Upadhye, PhD, indicates bioavailability enhancement with formulation and dose form flexibility can be achieved through the application of HME technology to produce stable drug formulations and increased development success rates.
Capsugel Unveils New Facility; Significantly Expands Capability July 6, 2015
Capsugel recently announced it has completed construction of a new pharmaceutical spray-dried dispersion (SDD) commercial manufacturing facility at its site...Presentation: Strategies for Amorphous Solid Dispersion Product Development
In this presentation, Dr. Schlesinger demonstrates how to leverage a combination of measured and calculated molecular properties, bio-performance modeling, and a strategic understanding of the product TPP to identify a technology to enable exposure and an appropriate drug product design…..
